Mylan will pay the Department of Justice $465 million in a settlement over its pricing and classification of the EpiPen through Medicaid, the pharmaceutical company announced Friday.

Mylan, which came under fire this summer for systematically hiking the price of the life-saving device, at the same time allegedly improperly classified the EpiPen as a generic drug. That led Medicaid and Medicare to both overpay for the product.

The DOJ’s question centered on the EpiPen’s classification through Medicaid and Medicare. The EpiPen had been classified as a non-innovator drug, affecting how the federal programs calculated rebates. Read more…

More about Epipen, Mylan, and Business

Continue at source – 

Mylan to pay $465 million over Medicaid pricing of EpiPen